DUBLIN--(BUSINESS WIRE)--The "Age-Related Macular Degeneration Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering.
This report provides the most up-to-date information on key pipeline products in the global Age-Related Macular Degeneration market. It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages
The report provides Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes
The report provides Age-Related Macular Degeneration pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company
The report provides Age-Related Macular Degeneration pipeline products by the company.
Short-term Launch Highlights
Find out which Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2020.
For more information about this report visit https://www.researchandmarkets.com/research/7kzwr8/agerelated?w=4
